A study for a 33 year old man who takes Vesicare - from FDA reports


Summary

71 males aged 33 (±5) who take the same drug are studied. This is a personalized study for a 33 year old male patient who has Benign Prostatic Hyperplasia, Hyperthyroid. The study is created by eHealthMe based on reports from FDA.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA since 1977. Our tools are simple to use, anonymous and free. Start now >>>


On Oct, 12, 2017

71 males aged 33 (±5) who take Vesicare are studied.


Number of reports submitted per year:

Vesicare for a 33-year old man.

Information of the patient in this study:

  • Age: 33
  • Gender: male
  • Conditions: Benign Prostatic Hyperplasia, Hyperthyroid
  • Drugs taken:
    • Vesicare (solifenacin succinate)

eHealthMe real world results:

Comparison with this patient's adverse outcomes:

  • Lose Weight: 0 (0% of males aged 33 (±5) who take the drug)

As an adverse outcome could be a symptom of a condition, additional studies are listed to help identify the cause: for example, regardless of which drug is taken, how many female HBP patients aged 50 (±5) have nausea

As an adverse outcome could be a side effect of a drug, additional studies are listed to help identify the cause: for example, how many female Aspirin users aged 50 (±5) have nausea

Most common side effects over time

< 1 month:
  • suicidal ideation
  • depressed mood
  • depression
  • anger
  • confusional state
  • dizziness
  • urination - painful
  • urine output decreased
  • aggression
  • heart palpitations
1 - 6 months:
  • dry eyes
  • dry mouth
6 - 12 months:
  • sepsis
  • ards (acute respiratory distress syndrome)
1 - 2 years:
n/a
2 - 5 years:
n/a
5 - 10 years:
  • emotional disorder
  • depression
  • personality change
10+ years:
n/a
not specified:
  • drug ineffective
  • fatigue
  • dizziness
  • oedema peripheral
  • blood glucose increased
  • skin discoloration
  • feeling hot
  • lymphocyte count decreased
  • eosinophil count decreased
  • numbness and tingling

Top conditions involved for these people *:

  • Multiple Sclerosis (22 people, 30.99%)
  • Gait Disturbance (11 people, 15.49%)
  • Hypertonic Bladder (10 people, 14.08%)
  • Relapsing-Remitting Multiple Sclerosis (8 people, 11.27%)
  • Bladder Disorder (7 people, 9.86%)

Top co-used drugs for these people *:

  • Tysabri (14 people, 19.72%)
  • Gilenya (12 people, 16.90%)
  • Lyrica (11 people, 15.49%)
  • Baclofen (10 people, 14.08%)
  • Neurontin (8 people, 11.27%)

* Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Subscribe to the study: get notified of updates to the study.

You can also:

Expand the study to include reports from both FDA and eHealthMe

Expand this study to include FDA and eHealthMe reports

What are the drugs?

What are the conditions?

What are the symtoms?

Could your drugs cause:

Could your conditions cause:

Related studies:

Can you answer these questions?

More questions for: Vesicare, Benign prostatic hyperplasia, Hyperthyroid, Lose weight

You may be interested in these reviews

More reviews for: Vesicare, Benign prostatic hyperplasia, Hyperthyroid, Lose weight